Alzheimer’s senescent cell combination therapy presents promise
Evidence from a Phase I trial suggests that the tyrosine…
Evidence from a Phase I trial suggests that the tyrosine kinase inhibitor dasatinib in combination with quercetin clears amyloid from the brain and lowers inflammation in the blood.